Business Context and Reporting Period
Envoy Medical, Inc. (formerly Anzu Special Acquisition Corp I) filed a Form 8-K on December 19, 2024. The company is an emerging growth company incorporated in Delaware with principal executive offices in White Bear Lake, MN. Its Class A Common Stock (COCH) and Redeemable Warrants (COCHW) trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a Current Report regarding a material definitive agreement and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes
The primary material change reported is the execution of Amendment No. 2 to the Common Stock Purchase Warrant (the "Second Shortfall Warrant Amendment") on December 19, 2024, between Envoy Medical and the Meteora FPA Parties (Meteora Special Opportunity Fund I, LP, Meteora Capital Partners, LP, Meteora Select Trading Opportunities Master, LP, and Meteora Strategic Capital, LLC). This amendment extends the expiration date of 3,874,394 Shortfall Warrants by 12 months, from December 31, 2024, to December 31, 2025. These warrants allow the purchase of up to 3,874,394 shares of Class A Common Stock at an exercise price of $10.46 per share.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of general business risks. The only specific contingency noted is the extension of the warrant expiration date, which alters the timeline for potential dilution or exercise of the Shortfall Warrants. The issuance and resale of the Shortfall Warrant Shares and Warrants are registered under Form S-1 (File No. 333-276590), declared effective on May 2, 2024.
Investor Verification Checklist
- Verify the full terms of the Second Shortfall Warrant Amendment attached as Exhibit 10.1.
- Confirm the current market price of Class A Common Stock relative to the $10.46 exercise price of the Shortfall Warrants.
- Review the company's most recent 10-K or 10-Q for actual financial performance, as this 8-K contains no financial data.
- Monitor the status of the OTC Equity Prepaid Forward Transaction initiated in April 2023.